Literature DB >> 17001312

Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals.

M K Evans1, C-R Yu, A Lohani, R M Mahdi, X Liu, A R Trzeciak, C E Egwuagu.   

Abstract

DNA-hypermethylation of SOCS genes in breast, ovarian, squamous cell and hepatocellular carcinoma has led to speculation that silencing of SOCS1 and SOCS3 genes might promote oncogenic transformation of epithelial tissues. To examine whether transcriptional silencing of SOCS genes is a common feature of human carcinoma, we have investigated regulation of SOCS genes expression by IFNgamma, IGF-1 and ionizing radiation, in a normal human mammary epithelial cell line (AG11134), two breast-cancer cell lines (MCF-7, HCC1937) and three prostate cancer cell lines. Compared to normal breast cells, we observe a high level constitutive expression of SOCS2, SOCS3, SOCS5, SOCS6, SOCS7, CIS and/or SOCS1 genes in the human cancer cells. In MCF-7 and HCC1937 breast-cancer cells, transcription of SOCS1 is dramatically up-regulated by IFNgamma and/or ionizing-radiation while SOCS3 is transiently down-regulated by IFNgamma and IGF-1, suggesting that SOCS genes are not silenced in these cells by the epigenetic mechanism of DNA-hypermethylation. We further show that the kinetics of SOCS1-mediated feedback inhibition of IFNgamma signaling is comparable to normal breast cells, indicating that the SOCS1 protein in breast-cancer cells is functional. We provide direct evidence that STAT3 pathways are constitutively activated in MCF-7 and HCC1937 cells and may drive the aberrant persistent activation of SOCS genes in breast-cancer cells. Our data therefore suggest that elevated expression of SOCS genes is a specific lesion of breast-cancer cells that may confer resistance to proinflammatory cytokines and trophic factors, by shutting down STAT1/STAT5 signaling that mediate essential functions in the mammary gland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17001312     DOI: 10.1038/sj.onc.1209993

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  SOCS5 and SOCS6 have similar expression patterns in normal and cancer tissues.

Authors:  Sungpil Yoon; Young-Su Yi; Sang Soo Kim; Ju-Hwa Kim; Won Sang Park; Suk Woo Nam
Journal:  Tumour Biol       Date:  2011-11-12

2.  Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis.

Authors:  Qing-Xin Zhou; Xing-Ming Jiang; Zhi-Dong Wang; Chun-Long Li; Yun-Fu Cui
Journal:  Med Oncol       Date:  2015-03-06       Impact factor: 3.064

3.  Role of SOCS-1 Gene on Melanoma Cell Growth and Tumor Development.

Authors:  Jorge A Borin Scutti; Alisson Leonardo Matsuo; Felipe Valença Pereira; Mariana Hiromi Massaoka; Carlos Rogério Figueiredo; Dayson Friaça Moreira; José Ernesto Belizário; Luiz R Travassos
Journal:  Transl Oncol       Date:  2011-04-01       Impact factor: 4.243

4.  Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer.

Authors:  Walid Sasi; Wen G Jiang; Anup Sharma; Kefah Mokbel
Journal:  BMC Cancer       Date:  2010-04-30       Impact factor: 4.430

5.  Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling.

Authors:  Junichi Inokuchi; Alice Lau; Darren R Tyson; David K Ornstein
Journal:  Carcinogenesis       Date:  2009-04-07       Impact factor: 4.944

6.  SOCS3 deletion in T lymphocytes suppresses development of chronic ocular inflammation via upregulation of CTLA-4 and expansion of regulatory T cells.

Authors:  Cheng-Rong Yu; Sung-Hye Kim; Rashid M Mahdi; Charles E Egwuagu
Journal:  J Immunol       Date:  2013-10-07       Impact factor: 5.422

Review 7.  Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas.

Authors:  Emily C Brantley; Etty N Benveniste
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

Review 8.  Signal transducer and activator of transcription 5A/B in prostate and breast cancers.

Authors:  Shyh-Han Tan; Marja T Nevalainen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

Review 9.  Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer.

Authors:  Zhiyong Liao; Jacqueline Lutz; Marja T Nevalainen
Journal:  Int J Biochem Cell Biol       Date:  2009-11-13       Impact factor: 5.085

Review 10.  Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response.

Authors:  Michelle von Locquenghien; Catalina Rozalén; Toni Celià-Terrassa
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.